Doctors Talk Psychedelics: Ketamine, Psilocybin, MDMA

Psychedelics are everywhere right now—and most physicians still feel uneasy even saying the words out loud. In this episode, we have a no-hype conversation about ketamine, psilocybin, MDMA, and what these therapies could mean for patients with refractory depression, anxiety, and PTSD.

Topics: Mental Health, Emerging Treatments, Clinical Practice

Timestamps:

00:00 – Why psychedelics in medicine makes doctors uncomfortable

01:26 – Clinical scenario: "nothing is working" for severe depression/anxiety

03:44 – The lineup: ketamine, MDMA, LSD, psilocybin

04:07 – Skepticism: "not FDA approved," limited robust data

05:23 – A Colorado retreat enters the conversation

09:20 – The hard part: tapering off meds safely, risks, close follow-up

10:10 – Outcome: "first time I feel better" after the retreat

13:16 – Who psychedelics are NOT for (bipolar/psychotic disorders risk)

14:07 – What the research hints at (and what we still don't know)

16:20 – Dr. Parker shares his personal experience and why this topic matters

28:40 – Ketamine: what it's used for, what's legit, what's questionable

34:21 – Takeaways: hope, ambiguity, and why this deserves a real conversation